Association between regular antithrombotic drugs use and Nonbiliary Acute Pancreatitis risk: a prospective cohort study

Chenyang Wei[1,2,†], Ningning Mi[1,2,3,†], Jinyu Zhao[1,2], Pengfei Li[1,2], Zhengping An[1,2], Sheng Chen[1,2], Yanyan Lin[1,2], Ping Yue[1,2], Jinqiu Yuan[3*], Wenbo Meng[1,2*]

[1]The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China;

[2]Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China;

[3]Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.

*These authors are the corresponding authors.

[†]Chenyang Wei and Ningning Mi have contributed equally to this work.

Correspondence:

Wenbo Meng, Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China. Email: mengwb@lzu.edu.cn;

Jinqiu Yuan, Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. Email: yuanjq5@mail.sysu.edu.cn.

ABSTRACT

BACKGROUND

Antithrombotic drugs are widely used for the prevention of cardiovascular disease; however, their association with nonbiliary acute pancreatitis remains unclear. To investigate the association between regular use of antithrombotic drugs and the risk of developing nonbiliary acute pancreatitis.

METHODS

This prospective cohort study included 431,754 participants who did not have acute pancreatitis, gallstones, or cancer. Incident nonbiliary acute pancreatitis cases were identified through primary healthcare and hospitalization data, excluding gallstone-related cases. Cox proportional hazards models, adjusted for sociodemographic characteristics, lifestyle, comorbidities, and medication, were used to estimate the association with regular antithrombotic drug use.

RESULTS

During a median follow-up period of 13.73 years, 2,189 cases of nonbiliary acute pancreatitis were recorded. Users of antithrombotic drugs had a 31% higher risk of developing nonbiliary acute pancreatitis than non-users (hazard ratio [HR], 1.31; 95% confidence interval [CI], 1.08-1.61; p=0.007). Risk varied by specific agent: clopidogrel was associated with a 53% increased risk (HR, 1.53; 95% CI, 1.08-2.16; p=0.016). For warfarin, the overall association was not statistically significant (HR,

1.32; 95% CI, 0.97-1.80; p=0.076); however, subgroup analysis indicated that the

association was confined to participants without diabetes (P for interaction, 0.015; HR,

1.64; 95% CI, 1.15-2.35; p=0.007). There was no significant association between

low-dose aspirin and use of dipyridamole.

CONCLUSION

Regular use of antithrombotic drugs, particularly clopidogrel, was associated with an

increased risk of developing nonbiliary acute pancreatitis. The risk associated with

warfarin was specific to participants without diabetes.

Key Words: Antithrombotic; Acute pancreatitis; Type 2 diabetes mellitus;

Hyperlipidemia; Cohort study.

INTRODUCTION

Acute pancreatitis (AP) is an inflammatory disorder of the pancreas, which is associated with substantial morbidity and mortality, and it imposes a substantial burden on healthcare systems worldwide [1]. In severe cases, it can progress to systemic inflammation and multiple organ failure, with a mortality rate as high as 85% [2]. The etiological spectrum of AP has significant geographical variation; in Western countries, biliary disease is the leading cause, followed by alcoholic and hypertriglyceridemia-induced pancreatitis. However, in Asian countries, including China, hypertriglyceridemia accounts for a substantially higher percentage of cases [3]. The rapidly increasing prevalence of hypertriglyceridemia-related AP has established it as a pressing global health concern [4,5].

In addition to the traditional causes, medications are recognized as potentially inducing AP [6,7]. Antithrombotic agents have drawn particular attention due to their widespread use in patients with cardiovascular diseases [8,9]. However, evidence of the association between the use of these drugs and the risk of developing AP remains controversial, and consensus has not yet been reached. Evidence from animal models suggests that there is a potential protective effect; pre-treatment with low-dose warfarin can alleviate ischemia/reperfusion-induced pancreatic injury via this mechanism [10,11]. A recent large-scale clinical study also reported that among patients with established AP, the use of low-dose aspirin was associated with lower

mortality and a reduced risk of complications [12]. In contrast, a study had reported

that actively using clopidogrel were associated with an increased risk of acute

pancreatitis [13]. This conflicting body of evidence creates a dilemma for clinicians

who are managing a substantial cohort of patients with cardiovascular disease, and

who require long-term antithrombotic therapy, making it challenging to assess their

potential risk of developing AP.

Given these conflicting findings, a rigorous investigation is warranted to clarify

the relationship between the use of antithrombotic drugs and the risk of developing AP.

If these drugs be confirmed as a risk factor, their cardiovascular benefits must be

rigorously weighed against the risk of developing AP, in clinical decision-making,

necessitating increased clinical vigilance among prescribers. Conversely, evidence of

a protective effect would justify further studies into the mechanisms of action. To

address this knowledge gap, a prospective analysis of the association between the use

of antithrombotic drugs and the risk of developing AP, in a large cohort of 431,754

individuals, was conducted.

MATERIALS AND METHODS

Study cohort

Data from the study cohort was obtained from the United Kingdom (UK)

Biobank, a large prospective cohort of >500,000 participants, aged 37-73 years. The

cohort was established between 2006 and 2010 across 22 assessment centers in

England, Wales, and Scotland. The participants were followed-up regularly for data

updates. During recruitment, all participants completed a baseline questionnaire and

underwent assessments that included physical measurements and detailed information

on lifestyle and use of medication. Further details regarding the UK Biobank cohort

have been published elsewhere [14]. Participants with a baseline diagnosis of cancer,

gallstone disease, or acute pancreatitis were excluded. To prevent gallstone disease

from confounding the results, participants who developed acute AP during follow-up,

but had previously been diagnosed with gallstone disease, were excluded. Participants

with incomplete follow-up data were also excluded. The final analytical cohort

comprised 431,754 participants (Supplementary Figure 1). All diagnoses were based

on the International Classification of Diseases-10 (ICD-10) diagnostic criteria.

Assessment of exposure

The primary exposure was defined as regular use of antithrombotic drugs, at

baseline, including anticoagulants and antiplatelet drugs. The specific medications

that were considered were: warfarin, low-dose aspirin, clopidogrel, and dipyridamole.

At baseline, the regular use of antithrombotic drugs was first assessed from

participants using a touchscreen questionnaire, and confirmed during verbal

interviews with trained staff. In the touchscreen questionnaire, participants were asked,

"Do you regularly take any other prescription medications?". "Regular use" of

prescription medications was defined as taking them on a long-term and scheduled

basis, whether daily, weekly, or monthly (e.g., depot injections), as reported during

the verbal interview. Short-term medications, such as courses of antibiotics, were

excluded. If the participant selected "Yes" or "Do not know", the interviewer would

ask; "In the touchscreen, you said you are taking regular prescription medications.

Can you now tell me what these are?". Information regarding the use of

antithrombotic drugs was recorded using a coded list. The antithrombotic drugs

recorded included warfarin, low-molecular-weight heparin, low-dose aspirin,

clopidogrel, and dipyridamole. Information regarding the dose and duration of use of

antithrombotic agents was not collected. Detailed questions on the use of

antithrombotic agents can be found on the UK Biobank website.

Ascertainment of outcome

Incident cases of AP were identified from hospital records linked to the Health

and Social Care Information Centre (England and Wales) and the National Health

Service Central Register (Scotland), using the ICD-10 code, K85. The diagnosis of AP

was further validated if at least two of the following three criteria were fulfilled: (1)

characteristic abdominal pain, (2) serum amylase and/or lipase levels greater than

three times the upper limit of normal, and (3) imaging findings consistent with AP on

contrast-enhanced computed tomography or magnetic resonance imaging. Among the

participants with AP, nonbiliary AP was confirmed by excluding those with a

concomitant or prior diagnosis of gallstone disease. Assessment of the severity of

disease was not performed due to the lack of detailed clinical and laboratory data in

the databases.

Assessment of covariates

At enrollment, information on covariates was collected through the touchscreen

questionnaire and face-to-face interviews, covering socio-demographic characteristics,

anthropometric measurements, lifestyle factors, medical history, and use of

medication. Specifically, the data included: (1) socio-demographic factors: age, sex,

ethnicity and socioeconomic status (measured using the Index of Multiple Deprivation

[IMD], directly obtained from the UK Biobank); (2) anthropometric data: height and

weight, and body mass index (BMI), calculated as kg/m^2; (3) lifestyle factors:

smoking status, alcohol consumption, physical activity (assessed using the short-form

International Physical Activity Questionnaire, and healthy diet (defined according to

American Heart Association guidelines; Supplementary Table 2); (4) medical history:

type 2 diabetes, hypertension, hyperlipidemia, and cardiovascular disease; (5) use of

medication: nonsteroidal antiinflammatory drugs (NSAIDs), hypolipidemic drugs,

multivitamin and mineral supplements.

Statistical analysis

Baseline characteristics are presented as mean (standard deviation, SD) for

continuous variables and as count (percentage) for categorical variables. Person-years

of follow-up were calculated from the date of assessment for each participant until the

first diagnosis of AP, death, or the end of follow-up (May 31, 2022), whichever was

first.

Cumulative incidence curves for nonbiliary AP were generated to compare

non-users of antithrombotic drugs with users of antithrombotic drugs, including

anticoagulants, antiplatelet agents, and specific medications. Initially, a crude model

was constructed to determine the association between the use of antithrombotic drugs

and the risk of developing nonbiliary AP. Next, three adjusted models were generated:

Model 1 was adjusted for age, sex, ethnicity, and IMD; Model 2 was further adjusted

for BMI, smoking, alcohol consumption, physical activity, and healthy diet; and

Model 3 was additionally adjusted for the presence of type 2 diabetes, hypertension,

or hyperlipidemia, use of NSAIDs, use of hypolipidemic drugs, and use of

multivitamins and mineral supplements. The proportional hazards assumption was

verified using Schoenfeld residuals for all models, and there were no violations.

Subgroup analyses were performed according to pharmacological class

(anticoagulants or antiplatelet agents) and individual drugs (warfarin, aspirin,

clopidogrel, and dipyridamole). The results from the most fully adjusted model

(Model 3) are reported as the primary findings of this study.

The potential moderating effects of age, sex, BMI, smoking status, alcohol

consumption, physical activity, healthy diet, presence of type 2 diabetes, hypertension,

or hyperlipidemia, NSAID intake, use of hypolipidemic drugs, and use of

multivitamins and mineral supplements, were evaluated using stratified analysis and

interaction testing with a likelihood ratio test. Given that the presence of type 2

diabetes and hyperlipidemia suggested that there was a potential effect modification

in the overall analysis, their interaction effects were tested in the aforementioned

stratified medication analyses.

To evaluate the robustness of the findings, several sensitivity analyses were

performed: (1) further adjustment for history of cardiovascular diseases in Model 3,

as Model 4, to assess the extent to which the association could be explained by

pre-existing cardiovascular conditions; (2) exclusion of participants who developed

the outcome within the first year of follow-up, to minimize reverse causality; and (3)

a propensity score matching analysis to evaluate the effect of the use of

antithrombotic drugs on the risk of developing nonbiliary AP.

All analyses were performed using R version 4.5.1. Statistical significance was

set as two-tailed p<0.05.

RESULTS

Baseline characteristics of participants

Table 1 presents the baseline characteristics of the study cohort, stratified by use

of antithrombotic drugs. There were 431,754 participants, of whom 11,140 used

antithrombotic drugs. Among these, 4,452 used anticoagulants only, 6,610 used

antiplatelet agents only, and 78 used antiplatelet agents and anti-coagulants.

Regarding specific medications, 4,397 used warfarin, 2,514 used low-dose aspirin,

950 used dipyridamole, 2,818 used clopidogrel, and 93 used aspirin and

clopidogrel. Users of antithrombotic drugs were more likely to be older, male,

smokers, consumers of alcohol, and have a higher prevalence of comorbidities,

including type 2 diabetes, hypertension, and hyperlipidemia.

Use of antithrombotic drugs and the risk of developing Nonbiliary AP

During a median follow-up of 13.73 years, 2,189 new participants with nonbiliary AP were recorded, including 109 who used antithrombotic drugs and 2,080 who did not use antithrombotic drugs. Compared with non-users, there was a higher cumulative incidence of AP in users, particularly among users of anticoagulants and clopidogrel (Figure 1a, b, and c).

In the crude model, the use of antithrombotic drugs was associated with a 74% increased risk of developing nonbiliary AP (hazard ratio [HR], 1.74; 95% confidence interval [CI], 1.44-2.12; p<0.001). After adjusting for age, sex, ethnicity, and IMD (Model 1), the HR was 1.66 (95% CI, 1.37-2.02; p<0.001). The association attenuated somewhat but remained significant after further adjustment for lifestyle factors (Model 2) (HR, 1.44; 95% CI, 1.18-1.75; p<0.001). In Model 3, which was further adjusted for comorbidities and use of medication, the result did not change substantially (HR, 1.31; 95% CI, 1.08-1.61; p=0.007) (Table 2). In the analysis by pharmacological class, use of anticoagulants had a significantly increased risk (HR, 1.37; 95% CI, 1.01-1.86; p=0.040). Specifically, warfarin showed a trend towards an increased risk, although it did not reach statistical significance (HR, 1.32; 95% CI, 0.97-1.80; p=0.076). Analysis of other anticoagulants could not be performed or yielded imprecise results due to limitations in sample size. The overall association for antiplatelet agents was at the margin of statistical significance (HR, 1.27; 95% CI, 0.98-1.64; p=0.071). The use of clopidogrel was associated with a significantly increased risk (HR, 1.53; 95% CI, 1.08-2.16; p=0.016), whereas aspirin (HR, 1.02; 95%

CI, 0.65-1.61; p=0.934) and dipyridamole (HR, 0.95; 95% CI, 0.45-2.00; p=0.890)

did not have a significant association (Figure 2).

Subgroup analysis

The analysis revealed significant interactions; the association between overall

use of antithrombotic drugs and the risk of developing nonbiliary AP varied

depending on the presence of diabetes (P for interaction = 0.001) or hyperlipidemia (P

for interaction = 0.044). Specifically, among participants without diabetes, the use of

antithrombotic drugs was significantly associated with an increased risk of developing

nonbiliary AP (HR, 1.52; 95% CI, 1.19-1.96; p=0.001). However, this association was

not observed for participants with diabetes (HR, 1.08; 95% CI, 0.78-1.50; p=0.644).

The increased risk was more pronounced for participants without hyperlipidemia (HR,

1.96; 95% CI, 1.22-3.15; p=0.006), while the association was weaker and did not

reach statistical significance for participants with hyperlipidemia (HR, 1.23; 95% CI,

0.99-1.53; p=0.063) (Figure 3).

Stratified by drug class, the effect of modification by diabetes and

hyperlipidemia were evaluated. There was a significant interaction with diabetes

among users of anticoagulants (P for interaction = 0.019). Given that warfarin was the

predominant anticoagulant (other anticoagulants were not analyzed due to insufficient

sample size), a subgroup analysis focusing on warfarin confirmed that this interaction

remained statistically significant (P for interaction = 0.015). Specifically, for

participants without diabetes, conventional use of warfarin was associated with a 64%

increased risk of developing non-biliary AP (HR, 1.64; 95% CI, 1.15-2.35), whereas

there was no statistically significant association for participants with diabetes.

Furthermore, hyperlipidemia did not have a significant modifying effect on

anticoagulants. For users of antiplatelet agents, including low-dose aspirin,

clopidogrel, and dipyridamole, there was no significant interaction with diabetes or

hyperlipidemia (Supplementary Table 3).

Sensitivity analysis

The association between the use of anticoagulants and the risk of developing

nonbiliary AP remained stable after further adjustment for a history of cardiovascular

disease (HR, 1.31; 95% CI, 1.08-1.61). After excluding participants with nonbiliary

AP that developed within the first year of follow-up, the association remained

statistically significant (HR, 1.25; 95% CI, 1.01-1.54; Supplementary Table 4). In a

sensitivity analysis using a propensity score-matched cohort of 55,694 participants

(Supplementary Table 5), regular use of antithrombotic drugs was associated with a

37% increased risk of developing nonbiliary AP (HR, 1.37; 95% CI, 1.01-1.86).

DISCUSSION

In this prospective cohort study, using data from >430,000 participants, regular

use of antithrombotic drugs was associated with a 31% increased risk of developing

nonbiliary AP, after adjusting for potential confounding factors. In-depth analysis

revealed significant heterogeneity in the level of risk; the increased risk was primarily

concentrated in users of clopidogrel (HR, 1.53), whereas warfarin had only a trend

towards increased risk, and aspirin and dipyridamole did not have a significant risk.

Notably, the association remained robust in a sensitivity analysis, with further

adjustment for a history of cardiovascular diseases. This consistency strengthens the

argument for there being an independent association between the use of

antithrombotic drugs and the risk of developing nonbiliary AP, beyond the influence

of underlying cardiovascular conditions.

To the best of our knowledge, this is the first prospective cohort study, in which

the association between the use of antithrombotic drugs and the risk of developing

nonbiliary AP has been investigated. Although previous studies, on the association

between the use of antithrombotic drugs and disorders of the stomach, small intestine

[15,16], and liver [17,18], and their potential adverse effects on the pancreas, have

received limited attention. In 2015, based on a population-based case-control study in

Taiwan, Lai et al. reported a significantly increased risk of developing AP in patients

actively using clopidogrel (adjusted odds ratio, 8.46; 95% CI, 5.25–13.7). The study

was a population-based case-control design and included 5,644 patients with AP,

significantly enhancing the reliability of the results [13]. The results strongly support

the findings of the present study. Moreover, in the present study, diabetes mellitus

significantly modified the association between warfarin and the risk of developing

nonbiliary AP, and these findings provide important evidence for personalized risk

assessment in clinical practice.

From the results of the present study, a potential mechanism for the increased

risk of developing nonbiliary AP in users of clopidogrel, is proposed. Clopidogrel, as

a P2Y12 receptor antagonist, might contribute to pancreatic injury by affecting P2Y12

receptors on pericytes in the pancreatic microcirculation. Recent studies have shown

that P2Y12 receptors are also expressed on vascular smooth muscle cells (VSMCs),

and their activation inhibits the cAMP/protein kinase A pathway [19]. This inhibition

effect leads to dephosphorylation of the cytoskeletal regulator, cofilin, which

promotes actin depolymerization and enhances cell motility [20,21]. Given

the high degree of homology between VSMCs and pericytes, and the established

expression of P2Y12 receptors in pericytes [22], pancreatic pericytes also likely to

express functional P2Y12 receptors. Signals transmitted through these receptors

regulate cytoskeletal proteins such as actin-depolymerizing factors, thereby

maintaining pericyte adhesion capacity and cytoskeletal plasticity. Clopidogrel

antagonism disrupts this regulation, reducing cytoskeletal remodeling and increasing

pericyte rigidity. This disruption effect compromises their capillary support function

and connections with endothelial cells, thereby impairing the integrity of the

microvascular barrier. The consequent increase in vascular permeability promotes the

extravasation of inflammatory mediators and leukocyte infiltration, ultimately

triggering or exacerbating local pancreatic inflammation [23,24]. In contrast, aspirin

inhibits thromboxane A2 synthesis by acetylating platelet COX-1, an action that is

highly restricted to platelets [25]. Dipyridamole enhances the intracellular cAMP level

by inhibiting phosphodiesterase, thereby suppressing platelet activation and

promoting vasodilation, and it potentiates these effects by elevating the adenosine

level [26]. As neither drug directly interferes with the P2Y12 receptor signaling

pathway, there were no significant associations with the risk of developing nonbiliary

AP.

Subgroup analyses revealed that the association between the use of warfarin and

the risk of developing nonbiliary AP was modified by the presence of type 2 diabetes.

This association was statistically significant in individuals without diabetes, and it

was not significant in individuals with diabetes. The mechanism underlying the effect

modification remains unclear, and it can potentially be attributed to the balance

between vascular injury and anticoagulation. As a vitamin K antagonist, warfarin

inhibits the synthesis of multiple vitamin K-dependent proteins, including matrix Gla

protein (MGP). MGP is a key factor in maintaining vascular homeostasis and

suppressing calcification [27,28]. Warfarin may impair pancreatic microvascular

function by inducing vascular calcification through inhibition of MGP, ultimately

increasing the susceptibility of pancreatic tissue to inflammation. However, diabetes

status often co-exists with a hypercoagulable state, which itself constitutes a risk

factor for pancreatic microcirculatory dysfunction and AP [29–31]. In this context, the

anticoagulant effect of warfarin may partially improve pancreatic microcirculation,

thereby offsetting its potential risks via the MGP pathway. Conversely, the direct

injury mechanism of warfarin predominates in individuals without diabetes and

normal coagulation function. Furthermore, the extremely high baseline risk of

pancreatitis in patients with diabetes may partially mask the additional relative risk

posed by warfarin [32]. Further studies are required to explore the underlying

mechanisms.

This study had several strengths, including its prospective design, large sample

size, and extended follow-up period. Regular use of antithrombotic drugs is associated

with a higher risk of developing nonbiliary AP, after controlling for several potential

confounding factors, including lifestyle factors, use of medication, and health

conditions related to the use of antithrombotic drugs. The scale and depth of the

dataset permitted rigorous adjustment of potential confounders.

However, this study had several limitations. First, in the UK Biobank, data on

specific details, such as formulation, dosage, frequency, and duration of paracetamol

administration were not documented. This limitation hinders further analysis, and it

may introduce potential bias. Second, information on the use of antithrombotic drugs

was collected only once, at baseline, which prevented an assessment of how changes

in exposure over time might affect the risk of developing liver cancer. Third,

information on the severity of AP (according to the Revised Atlanta Classification)

was not available in the databases. This precluded further stratified analyses based on

severity of disease. Finally, as an observational study, a causal relationship cannot be

definitively established, and residual confounding from unmeasured variables cannot

be ruled out. These inherent limitations highlight the requirement for further

epidemiological and mechanistic studies.

CONCLUSIONS

This large prospective cohort study has identified that regular use of

antithrombotic drugs, particularly clopidogrel, is associated with an increased risk of

developing nonbiliary AP. Furthermore, underlying metabolic status was identified as

a key modifier of this risk. Notably, diabetes status had a negative modifying effect on

warfarin-associated risk, which was more pronounced in individuals without diabetes.

This counter-intuitive finding underscores the necessity for personalized risk

assessment in clinical decision-making for antithrombotic therapy, with vigilance

warranted in seemingly "healthy" cohorts. Future studies are required to elucidate the

underlying biological mechanisms, and to validate these findings at the level of

specific drug subtypes in high-quality cohorts.

LIST OF ABBREVIATIONS:

Abbreviations	Full name
AP	Acute Pancreatitis
BMI	Body Mass Index
CI	Confidence Interval
HR	Hazard Ratio
ICD-10	International Classification of Diseases-10
IMD	Index of Multiple Deprivation
Met	Metabolic Equivalent of Task
MGP	Matrix Gla Protein
NSAID	Nonsteroidal Anti-Inflammatory Drug
PSM	Propensity Score Matching
SD	Standard Deviation
UKB	UK Biobank
VSMCs	vascular smooth muscle cells

DECLARATIONS:

Ethics approval and consent to participate:

The UK Biobank has received ethical approval from the North West Multi-centre

Research Ethics Committee, the England and Wales Patient Information Advisory

Group and the Scottish Community Health Index Advisory Group. All participants

provided written informed consent prior to enrolment, and the analysis used

anonymous data.

Consent for publication:

Not Applicable.

Availability of data and materials:

All data used in this study was obtained from publicly available datasets UK

biobank (UKB). To access the data used in this study, researchers can apply for access

to the UKB through their website

(**https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access**).

Clinical Trial Number:

Not Applicable.

Competing interests:

The authors have no conflicts of interest to declare.

Funding:

This study was supported by the Major Program of the Gansu Province Joint

Scientific Research Fund (23JRRA1488); Major Scientific and Technological

Innovation Project of Gansu Provincial Health Industry (GSWSQNPY2024-10); and

the Lanzhou Talent Innovation and Entrepreneurship Project (2022-3-42).

Author Contributions:

Wei CY and Mi NN contributed to conceptualization and design; Wei CY, Mi

NN, Zhao JY, Li PF, An ZP and Chen S contributed to material preparation, data

acquisition; Yuan JQ , Lin YY and Yue P analyzed the data. Meng WB: supervised our

study. all authors participated in the writing and final approval of the manuscript.

Acknowledgements:

The authors thank the participants and staff of the UKB for their dedication and

contribution to the research.

REFERENCES

1. Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev

Gastroenterol Hepatol. 2019;16:479–96. https://doi.org/10.1038/s41575-019-0158-2

2. Zerem E. Treatment of severe acute pancreatitis and its complications. World J

Gastroenterol. 2014;20:13879–92. https://doi.org/10.3748/wjg.v20.i38.13879

3. Han K, Chen S, Song Y, Du C, Gao F, Liu S, et al. Burden of pancreatitis and

associated risk factors in China, 1990 to 2019: a systematic analysis for the Global

Burden of Disease Study 2019. Chin Med J (Engl). 2022;135:1340–7.

https://doi.org/10.1097/CM9.0000000000002164

4. van Geenen EJM, van der Peet DL, Bhagirath P, Mulder CJJ, Bruno MJ. Etiology

and diagnosis of acute biliary pancreatitis. Nat Rev Gastroenterol Hepatol.

2010;7:495–502. https://doi.org/10.1038/nrgastro.2010.114

5. Scherer J, Singh V, Pitchumoni CS, Yadav D. Issues in Hypertriglyceridemic

Pancreatitis - An Update. J Clin Gastroenterol. 2014;48:195–203.

https://doi.org/10.1097/01.mcg.0000436438.60145.5a

6. Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, et al.

Acute Pancreatitis: Diagnosis and Treatment. Drugs. 2022;82:1251–76. https://doi.org/10.1007/s40265-022-01766-4

7. Xie H, Jiang L, Peng J, Hu H, Han M, Zhao B. Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology. Front Pharmacol. 2025;16:1564127. https://doi.org/10.3389/fphar.2025.1564127

8. World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list [Internet]. World Health Organization; 2025 [cited 2025 Nov 2]. https://doi.org/10.2471/B09474

9. Zhang W, Yu E, Zhao W, Wu C, Ji X. Secondary prevention for intracranial atherosclerotic stenosis: Where we stand and challenges ahead. J Transl Int Med. 2024;12:537–9. https://doi.org/10.1515/jtim-2024-0037

10. Maduzia D, Ceranowicz P, Cieszkowski J, Gałązka K, Kuśnierz-Cabala B, Warzecha Z. Pretreatment with Warfarin Attenuates the Development of Ischemia/Reperfusion-Induced Acute Pancreatitis in Rats. Molecules. 2020;25:2493. https://doi.org/10.3390/molecules25112493

11. Konarska-Bajda K, Ceranowicz P, Cieszkowski J, Ginter G, Stempniewicz A, Gałązka K, et al. Administration of Warfarin Inhibits the Development of Cerulein-Induced Edematous Acute Pancreatitis in Rats. Biomolecules. 2023;13:948. https://doi.org/10.3390/biom13060948

12. Kim DH, Ko D, Elizondo Alatorre C, Lukens FJ, Porres JA, Palacios Argueta P, et al. Low-dose aspirin use is associated with reduced 30- and 90-day mortality and

overall improved outcomes in patients with acute pancreatitis: A multinational

multicenter analysis. Pancreatology. 2025;25:1080–5.

https://doi.org/10.1016/j.pan.2025.09.022

13. Lai S-W, Lin C-L, Liao K-F. Actively using clopidogrel correlates with an

increased risk of acute pancreatitis in Taiwan. Int J Cardiol. 2015;183:263–6.

https://doi.org/10.1016/j.ijcard.2014.09.042

14. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank:

an open access resource for identifying the causes of a wide range of complex

diseases of middle and old age. PLoS Med. 2015;12:e1001779.

https://doi.org/10.1371/journal.pmed.1001779

15. He C, Li Y, Jiang X, Jiang M-N, Zhao X-X, Ma S-R, et al. Progression of

Gastrointestinal Injury During Antiplatelet Therapy After Percutaneous Coronary

Intervention. JAMA Netw Open. 2023;6:e2343219.

https://doi.org/10.1001/jamanetworkopen.2023.43219

16. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al.

Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827–30.

https://doi.org/10.1136/bmj.310.6983.827

17. Alonso A, MacLehose RF, Chen LY, Bengtson LG, Chamberlain AM, Norby FL,

et al. Prospective study of oral anticoagulants and risk of liver injury in patients with

atrial fibrillation. Heart. British Cardiac Society; 2017;103:834–9.

https://doi.org/10.1136/heartjnl-2016-310586

18. Björnsson HK, Gudmundsson DO, Björnsson ES. Liver injury caused by oral

anticoagulants: A population-based retrospective cohort study. Liver Int. 2020;40:1895–900. https://doi.org/10.1111/liv.14559

19. Wihlborg A-K, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:1810–5. https://doi.org/10.1161/01.ATV.0000142376.30582.ed

20. Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J. 1998;336 (Pt 3):513–23. https://doi.org/10.1042/bj3360513

21. Pillois X, Chaulet H, Belloc I, Dupuch F, Desgranges C, Gadeau A-P. Nucleotide receptors involved in UTP-induced rat arterial smooth muscle cell migration. Circ Res. 2002;90:678–81. https://doi.org/10.1161/01.res.0000013700.98464.8e

22. Barnett SN, Cujba A-M, Yang L, Maceiras AR, Li S, Kedlian VR, et al. An organotypic atlas of human vascular cells. Nat Med. 2024;30:3468–81. https://doi.org/10.1038/s41591-024-03376-x

23. Cuthbertson CM, Christophi C. Disturbances of the microcirculation in acute pancreatitis. Br J Surg. 2006;93:518–30. https://doi.org/10.1002/bjs.5316

24. Menger MD, Plusczyk T, Vollmar B. Microcirculatory derangements in acute pancreatitis. J Hepatobiliary Pancreat Surg. 2001;8:187–94. https://doi.org/10.1007/s005340170015

25. Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. Eur Heart J. 2024;45:2362–76. https://doi.org/10.1093/eurheartj/ehae324

26. Ali Hassan R, Patel P. Dipyridamole. StatPearls [Internet]. Treasure Island (FL):

StatPearls Publishing; 2025 [cited 2025 Dec 21].

http://www.ncbi.nlm.nih.gov/books/NBK554455/. Accessed 21 Dec 2025

27. Danziger J. Vitamin K-dependent Proteins, Warfarin, and Vascular Calcification.

Clin J Am Soc Nephrol. 2008;3:1504–10. https://doi.org/10.2215/CJN.00770208

28. Willems BAG, Vermeer C, Reutelingsperger CPM, Schurgers LJ. The realm of

vitamin K dependent proteins: Shifting from coagulation toward calcification.

Molecular Nutrition & Food Research. 2014;58:1620–35.

https://doi.org/10.1002/mnfr.201300743

29. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications.

2001;15:44–54. https://doi.org/10.1016/s1056-8727(00)00132-x

30. Chung KH, Cho IR, Choi YH, Cho YD, Ryu JK, Lee SH, et al. Association

between diabetic status and risk of acute pancreatitis: A nationwide population-based

study. J Evid Based Med. 2024;17:588–96. https://doi.org/10.1111/jebm.12637

31. Yang L, He Z, Tang X, Liu J. Type 2 diabetes mellitus and the risk of acute

pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25:225–31.

https://doi.org/10.1097/MEG.0b013e32835af154

32. Urushihara H, Taketsuna M, Liu Y, Oda E, Nakamura M, Nishiuma S, et al.

Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational

study using a Japanese hospital database. PLoS One. 2012;7:e53224.

https://doi.org/10.1371/journal.pone.0053224

Figure 1. Cumulative Incidence of Nonbiliary AP Among Users of Antithrombotic Drugs with Non-Users. Estimated effects were calculated using the Cox model adjusted by age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, Hypolipidemic drug intake, multivitamin use and intake of mineral supplements. a shows the cumulative incidence of nonbiliary acute pancreatitis in overall antithrombotic drug users and non-users. b shows the cumulative incidence of nonbiliary acute pancreatitis in antiplatelet drug users, anticoagulant drug users, and non-users. c shows the cumulative incidence of nonbiliary acute pancreatitis in clopidogrel, warfarin, aspirin, dipyridamole users, and non-users.

531   **Abbreviations:** IMD, index of multiple deprivation; BMI, body mass index; NSAID,

532   nonsteroidal anti-inflammatory drug; AP, acute pancreatitis.

Drugs	Case/Person-years		HR（95%CI）	P
Antithrombotic	109/139161		1.31（1.08-1.61）	0.007
Anticoagulant_only	44/54597		1.37（1.01-1.86）	0.040
Warfarin	42/53935		1.32（0.97-1.80）	0.076
Antiplatelet_only	64/83690		1.27（0.98-1.64）	0.071
Clopidogrel	34/35488		1.53（1.08-2.16）	0.016
Aspirin	19/32473		1.02（0.65-1.61）	0.934
Dipyridamole	7/11735		0.95（0.45-2）	0.890

Figure 2. Forest plot for the association of antithrombotic drug use with the risk

of Nonbiliary AP.   The model was adjusted for age, gender, ethnicity, IMD, BMI,

smoking status, alcohol intake, physical activity, dietary characteristics, type 2

diabetes, hypertension, hyperlipidemia, NSAID intake, hypolipidemic drug intake,

multivitamin use, and mineral supplement intake;

Abbreviations: IMD , the Index of Multiple Deprivation; BMI, body mass index;

NSAID, nonsteroidal anti-inflammatory dr

Subgroup	non-antithrombotic use		antithrombotic use		Multivariate-adjusted HR(95% CI)	P Value	P for Interaction
	case	person-years	case	person-years			
Age							0.910
(35,55]	709	2525127	13	22793	1.19 (0.68-2.09)	0.546	
(55,65]	947	2390321	54	73533	1.28 (0.96-1.70)	0.088	
(65,75]	424	736694	42	42836	1.40 (1.00-1.94)	0.047	
Gender							0.889
Female	1020	3054433	32	42929	1.33 (0.93-1.92)	0.118	
Male	1060	2597708	77	96233	1.30 (1.02-1.66)	0.031	
BMI							
less than 25kg/m2	426	1880600	19	26497	1.71 (1.05-2.77)	0.03	
25-30 kg/m2	870	2428087	34	61463	1.14 (0.80-1.62)	0.479	
at least 30 kg/m2	777	1315281	56	50872	1.36 (1.03-1.80)	0.033	
Smoking							0.741
Yes	1101	2494024	69	78884	1.28 (0.99-1.65)	0.055	
No	968	3138831	40	59393	1.41 (1.02-1.96)	0.038	
Drinking							0.544
Never	526	1051145	33	34437	1.32 (0.91-1.90)	0.138	
Low	233	627878	8	13875	1.03 (0.50-2.12)	0.946	
Moderate	907	2809485	48	59700	1.47 (1.09-1.99)	0.012	
High	409	1159129	20	30975	1.19 (0.75-1.89)	0.464	
Physical Activity							0.650
Low	935	2856079	51	72992	1.55(1.02-2.33)	0.038	
Moderate	1145	2796062	58	66169	1.52(1.05-2.20)	0.027	
High	562	1823065	21	39167	1.00(0.64-1.57)	0.99	
Diet							0.968
Healthy	341	798247	27	23389	1.27 (0.95-1.70)	0.112	
Unhealthy	611	1789408	32	42241	1.36 (1.03-1.79)	0.028	
Hyperlipidemia							0.044
Yes	1301	2684075	91	116556	1.23 (0.99-1.53)	0.644	
No	779	2968066	18	22605	1.96 (1.22-3.15)	0.001	
Diabetes							0.010
Yes	461	440728	40	36479	1.08 (0.78-1.50)	0.015	
No	1619	5211413	69	102682	1.52 (1.19-1.96)	0.179	
Hypertension							0.614
Yes	1670	4087924	98	122365	1.30 (1.05-1.61)	0.063	
No	407	1559938	11	16782	1.54 (0.82-2.87)	0.006	
NSAIDs							0.676
Yes	360	942313	7	8732	1.19 (0.55-2.56)	0.659	
No	1720	4709828	102	130429	1.32 (1.07-1.62)	0.009	
Hypolipidemic drug							0.361
yes	539	934428	81	100727	1.40 (0.87-2.25)	0.162	
no	1541	4717713	28	38434	1.23 (0.99-1.53)	0.057	
Vitamin							0.583
Yes	328	844741	19	20443	1.43 (0.88-2.32)	0.144	
No	1752	4807400	90	118718	1.28 (1.03-1.60)	0.027	
Mineral							0.867
Yes	415	1229229	14	20387	1.20 (0.69-2.08)	0.514	
No	1665	4422912	95	118774	1.33 (1.07-1.65)	0.009	

0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50

Figure 3. Subgroup analyses of Antithrombotic Drugs Use and the risk of

Nonbiliary AP. Estimated effects were calculated using the Cox model adjusted by

age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity,

dietary characteristics, type 2 diabetes, hypertension, Hyperlipidemia, NSAID intake,

multivitamin use, Hypolipidemic drug intake and intake of mineral supplements;

Abbreviations: IMD, index of multiple deprivation; BMI, body mass index; NSAID,

nonsteroidal anti-inflammatory drug.

Table 1. Baseline characteristics of participants by antithrombotic use.

Characteristics	Antithrombotic use		Overall
	No	**Yes**	
Number of participants	(N=420614)	(N=11140)	(N=431754)
Anticoagulant only	/	4,452	/
Warfarin	/	4,397	/
Antiplatelet only	/	6,610	/
Low-dose Aspirin	/	2,514	/
Dipyridamole	/	950	/
Clopidogrel	/	2,818	/
Aspirin and Clopidogrel	/	93	/
Anticoagulant and Antiplatelet	/	78	/
Mean (SD) age	56.2 (8.10)	61.7 (6.26)	56.3 (8.11)

Male	195105 (46.4%)	7799 (70.0%)	202904 (47.0%)
White	396396 (94.2%)	10502 (94.3%)	406898 (94.2%)
Mean (SD) IMD	17.2 (13.8)	19.4 (15.3)	17.2 (13.8)
Mean (SD) BMI	27.3 (4.71)	29.2 (5.18)	27.4 (4.73)
Smoking	187613 (44.6%)	6454 (57.9%)	194067 (44.9%)
Drinking			
Never	79126 (18.8%)	2810 (25.2%)	81936 (19.0%)
Low	46553 (11.1%)	1104 (9.9%)	47657 (11.0%)
Moderate	207958 (49.4%)	4751 (42.6%)	212709 (49.3%)
High	86632 (20.6%)	2461 (22.1%)	89093 (20.6%)
Physical activity			
Low	59600 (14.2%)	1929 (17.3%)	61529 (14.3%)
Moderate	132826 (31.6%)	3379 (30.3%)	136205 (31.5%)
High	135361 (32.2%)	3047 (27.4%)	138408 (32.1%)
HealthyDiet	212118 (50.4%)	5768 (51.8%)	217886 (50.5%)
NASIDS	69906 (16.6%)	699 (6.3%)	70605 (16.4%)
Hypolipidemic drug	71717 (17.1%)	8142 (73.1%)	79859 (18.5%)
Vitamin	63113 (15.0%)	1636 (14.7%)	64749 (15.0%)
Mineral	91240 (21.7%)	1596 (14.3%)	92836 (21.5%)
Diabetes	34044 (8.1%)	3028 (27.2%)	37072 (8.6%)
Hypertension	305680 (72.7%)	9819 (88.1%)	315499 (73.1%)

Hyperlipidemia	201352 (47.9%)	9363 (84.0%)	210715 (48.8%)
Myocardial Infarction	16671 (4.0%)	439 (3.9%)	17110 (4.0%)
Coronary Heart Disease	22737 (5.4%)	599 (5.4%)	23336 (5.4%)
Myocardial Infarction	4624 (1.1%)	136 (1.2%)	4760 (1.1%)
Peripheral Vascular Disease	6987 (1.7%)	188 (1.7%)	7175 (1.7%)
Stroke	6638 (1.6%)	187 (1.7%)	6825 (1.6%)

561   Abbreviations: SD, standard deviation; IMD, index of multiple deprivation; BMI,

562   body mass index; NSAIDs, non-steroidal anti-inflammatory drugs;

563   Values are numbers (percentages) unless stated otherwise.

565   **Table 2. Associations between Antithrombotic use and risk of Nonbiliary Acute**

566   **Pancreatitis(n=431,754).**

	Antithrombotic use		p-value
Variables	**No （N=420,614）**	**Yes (N=11,140)**	
Case/person-years	2,080 / 5,652,141	109 / 139,161	
IR (per 10,000 person-years)	3.68	7.83	
Multivariate-adjusted HR (95% CI)			
Crude model	1.00 (Reference)	1.74 （1.44-2.12）	<0.001
model 1	1.00 (Reference)	1.66 （1.37-2.02）	<0.001
model 2	1.00 (Reference)	1.44 （1.18-1.75）	<0.001
model 3	1.00 (Reference)	1.31 （1.08-1.61）	0.007

Crude model: Unadjusted for covariates in the crude model; Model 1 adjusted for age,

gender, ethnicity, and Index of Multiple Deprivation (IMD); Model 2 additionally

adjusted for BMI, smoking status, alcohol intake, physical activity, and dietary

characteristics; Model 3 further adjusted for comorbidities and medication use on the

basis of Model 2, including type 2 diabetes, hypertension, hyperlipidemia, NSAID

intake, hypolipidemic drugs, multivitamins, and mineral supplements.

Abbreviations: IR, incidence rate; HR, hazard ratio; CI, confidence interval; BMI,

body mass index; NSAID, nonsteroidal anti-inflammatory drug.